Etiketter

Visar inlägg med etikett BMP. Visa alla inlägg
Visar inlägg med etikett BMP. Visa alla inlägg

onsdag 1 februari 2017

BMP, Smad ja osteoporosis

Haku 1.2. 2017 40 vastausta ja otan nämä talteen.

Items: 1 to 20 of 40


1.
Liu J, Lu C, Wu X, Zhang Z, Li J, Guo B, Li D, Liang C, Dang L, Pan X, Peng S, Lu A, Zhang B, Zhang G.
Sci Rep. 2017 Jan 27;7:41295. doi: 10.1038/srep41295.
The underlying mechanism of the reduced bone formation during the development of glucocorticoid-induced osteoporosis (GIO) remains unclear. Here, we found that the highly expressed CKIP-1 together with lowly expressed total and phosphorylated Smad1/5 in bone samples was accompanied by either the reduced serum bone formation markers in GIO patients or the decreased bone formation in GIO mice.
 In vitro studies showed that the highly expressed CKIP-1 could promote Smad1 ubiquitination to suppress the Smad-dependent BMP signaling and inhibit osteogenic differentiation and mineral deposition in MC3T3-E1 cells during glucocorticoid treatment. Further, the reduced bone formation in GIO mice could not only be prevented by osteoblasts-specific Ckip-1 ablation, but also be attenuated after osteoblasts-specific Smad1 overexpression. Moreover, osteoblasts-targeting CKIP-1 siRNA treatment also attenuated the bone formation reduction in GIO mice. These study suggest that the highly expressed CKIP-1 in osteoblasts could suppress the Smad-dependent BMP signaling and contribute to the bone formation reduction in GIO. Targeting osteoblastic CKIP-1 would be a novel bone anabolic strategy for GIO patients.Free Article
2.
Liu J, Liang C, Guo B, Wu X, Li D, Zhang Z, Zheng K, Dang L, He X, Lu C, Peng S, Pan X, Zhang BT, Lu A, Zhang G.
Aging Cell. 2017 Jan 13. doi: 10.1111/acel.12566. [Epub ahead of print]
 Emerging evidence indicates that the dysregulation of protein ubiquitination plays a crucial role in aging-associated diseases. Smad-dependent canonical BMP signaling pathway is indispensable for osteoblastic bone formation, which could be disrupted by the ubiquitination and subsequent proteasomal degradation of Smad1/5, the key molecules for BMP signaling transduction.
 However, whether the dysregulation of Smad1/5 ubiquitination and disrupted BMP signaling pathway is responsible for the age-related bone formation reduction is still underexplored. Pleckstrin homology domain-containing family O member 1 (PLEKHO1) is a previously identified ubiquitination-related molecule that could specifically target the linker region between the WW domains of Smurf1 to promote the ubiquitination of Smad1/5.
 Here, we found an age-related increase in the expression of PLEKHO1 in bone specimens from either fractured patients or aging rodents, which was associated with the age-related reduction in Smad-dependent BMP signaling and bone formation.
 By genetic approach, we demonstrated that loss of Plekho1 in osteoblasts could promote the Smad-dependent BMP signaling and alleviated the age-related bone formation reduction. In addition, osteoblast-specific Smad1 overexpression had beneficial effect on bone formation during aging, which could be counteracted after overexpressing Plekho1 within osteoblasts.
By pharmacological approach, we showed that osteoblast-targeted Plekho1 siRNA treatment could enhance Smad-dependent BMP signaling and promote bone formation in aging rodents. Taken together, it suggests that the increased PLEKHO1 could suppress Smad-dependent BMP signaling to inhibit bone formation during aging, indicating the translational potential of targeting PLEKHO1 in osteoblast as a novel bone anabolic strategy for reversing established osteoporosis during aging
Free Article
3.
Wang JY, Wen CS, Hung SC, Chen PW, Chiu JH.
J Ethnopharmacol. 2016 Dec 28. pii: S0378-8741(16)32324-8. doi: 10.1016/j.jep.2016.12.011. [Epub ahead of print]
PMID:
28040510
4.
Su XY, Zou X, Chen QZ, Zeng YH, Shao Y, He BC, Liu H.
J Cell Biochem. 2016 Dec 20. doi: 10.1002/jcb.25849. [Epub ahead of print]
PMID:
27996168
5.
Shao Y, Chen QZ, Zeng YH, Li Y, Ren WY, Zhou LY, Liu RX, Wu K, Yang JQ, Deng ZL, Yu Y, Sun WJ, He BC.
Int J Mol Med. 2016 Dec;38(6):1693-1702. doi: 10.3892/ijmm.2016.2782.
6.
Jeon EJ, Lee DH, Kim YJ, Ahn J, Kim MJ, Hwang JT, Hur J, Kim M, Jang YJ, Ha TY, Seo DH, Lee JS, Sung MJ, Jung CH.
Mol Nutr Food Res. 2016 Dec;60(12):2587-2601. doi: 10.1002/mnfr.201600257.
PMID:
27506630
7.
Zhang Y, Wang C, Cao Y, Gu Y, Zhang L.
Oncotarget. 2016 Jul 18. doi: 10.18632/oncotarget.10648. [Epub ahead of print]
The HECT-type ubiquitin ligase Smurf1 (Smad ubiquitination regulatory factor-1) plays the prominent role in regulation of bone formation, embryonic development, and tumorigenesis by directing the ubiquitin-proteasomal degradation of specific targets. In contrast with RING-type E3s, the catalytic HECT domain of Smurf1 firstly binds to and then transfers ubiquitin (Ub) molecules onto the substrates. The Smurf1-Ub interaction is required for Smurf1 catalytic ligase activity to promote substrate degradation. However, so far specific regulators or compounds controlling Smurf1-Ub interaction and the ligase activity have not been identified. Here we report two small molecule compounds targeting Ub binding region of HECT domain interrupt Smurf1-Ub contact, inhibit Smurf1 ligase activity and stabilize BMP signal components Smad1/5 protein level. Furthermore, these compounds increase BMP signal responsiveness and enhance osteoblastic activity in cultured cells. These findings provide a novel strategy through targeting Smurf1 ligase activity to potentially treat bone disorders such as osteoporosis.Free Article
8.
9.
Zhang ND, Han T, Huang BK, Rahman K, Jiang YP, Xu HT, Qin LP, Xin HL, Zhang QY, Li YM.
J Ethnopharmacol. 2016 Aug 2;189:61-80. doi: 10.1016/j.jep.2016.05.025. Review.
PMID:
27180315
10.
Kim DN, Joung YH, Darvin P, Kang DY, Sp N, Byun HJ, Cho KH, Park KD, Lee HK, Yang YM.
Mol Med Rep. 2016 Jul;14(1):460-6. doi: 10.3892/mmr.2016.5274

Huom. Cinnamaldehydi on  tutkittujen aineiden joukossa.
11.
Dong M, Jiao G, Liu H, Wu W, Li S, Wang Q, Xu D, Li X, Liu H, Chen Y.
Biol Trace Elem Res. 2016 Oct;173(2):306-15. doi: 10.1007/s12011-016-0686-3.
PMID:
27025722 Similar articles
12.
Guo M, James AW, Kwak JH, Shen J, Yokoyama KK, Ting K, Soo CB, Chiu RH.
Sci Rep. 2016 Mar 2;6:22378. doi: 10.1038/srep22378.
Silicon is essential for bone formation. A low-silicon diet leads to bone defects, and numerous animal models have demonstrated that silicon supplementation increases bone mineral density (BMD) and reduces bone fragility. However, the exact mechanism of this action has not been characterized. In this study, we aimed to determine the role of biological silicon in the induction of osteoblast differentiation and the possible underlying mechanism. We examined whether orthosilicic acid promotes collagen type 1 (COL-1) and osteocalcin synthesis through the bone morphogenetic protein-2 (BMP-2)/Smad1/5/runt-related transcription factor 2 (RUNX2) signaling pathway by investigating its effect in vitro at several concentrations on COL-1 and osteocalcin (OC) synthesis in human osteosarcoma cell lines (MG-63 and U2-OS). The expression of relevant proteins was detected by Western blotting following exposure to noggin, an inhibitor of BMP-2. In MG-63 cells, immunofluorescence methods were applied to detect changes in the expression of BMP-2, phosphorylated Smad1/5 (P-Smad1/5), and RUNX2. Furthermore, rat bone mesenchymal stem cells (BMSCs) were used to determine the effect of orthosilicic acid on osteogenic differentiation. Exposure to 10 μM orthosilicic acid markedly increased the expression of BMP-2, P-Smad1/5, RUNX2, COL-1, and osteocalcin in osteosarcoma cell lines. Enhanced ALP activity and the formation of mineralized nodules were also observed under these conditions. Furthermore, preconditioning with noggin inhibited the silicon-induced upregulation of P-Smad1/5, RUNX2, and COL-1 expression. In conclusion, the BMP-2/Smad1/5/RUNX2 signaling pathway participates in the silicon-mediated induction of COL-1 and osteocalcin synthesis, and orthosilicic acid promotes the osteogenic differentiation of rat BMSCs.Free PMC Article
13.
Chen C, Qin Y, Fang JP, Ni XY, Yao J, Wang HY, Ding K.
Acta Pharmacol Sin. 2015 Sep;36(9):1053-64. doi: 10.1038/aps.2015.65.
14.
Li Y, Fan L, Hu J, Zhang L, Liao L, Liu S, Wu D, Yang P, Shen L, Chen J, Jin Y.
Mol Ther. 2015 Aug;23(8):1349-57. doi: 10.1038/mt.2015.101.
MiR-26a exerts its effect by directly targeting Tob1, the negative regulator of BMP/Smad signaling pathway by binding to the 3'-untranslated region and thus repressing Tob1 protein expression. Our findings indicate that miR-26a may be a promising therapeutic candidate to enhance bone formation in treatment of osteoporosis and to promote bone regeneration in osteoporotic fracture healing. Free PMC Article
15.
Donoso O, Pino AM, Seitz G, Osses N, Rodríguez JP.
J Cell Biochem. 2015 Jul;116(7):1267-77. doi: 10.1002/jcb.25082.
PMID:
25640452
16.
Akkiraju H, Bonor J, Olli K, Bowen C, Bragdon B, Coombs H, Donahue LR, Duncan R, Nohe A.
J Orthop Res. 2015 Feb;33(2):208-15. doi: 10.1002/jor.22752.
17.
Güemes M, Garcia AJ, Rigueur D, Runke S, Wang W, Zhao G, Mayorga VH, Atti E, Tetradis S, Péault B, Lyons K, Miranda-Carboni GA, Krum SA.
J Bone Miner Res. 2014 Dec;29(12):2676-87. doi: 10.1002/jbmr.2296.
18.
Liu Y, Liu Y, Zhang R, Wang X, Huang F, Yan Z, Nie M, Huang J, Wang Y, Wang Y, Chen L, Yin L, He B, Deng Z.
Int J Biochem Cell Biol. 2014 Feb;47:47-56. doi: 10.1016/j.biocel.2013.11.018.
PMID:
24300824
19.
Xu G, Zhang C, Zhou J, Huang Z, Meng H.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2013 Sep;27(9):1144-7. Review. Chinese.
PMID:
24279032
20.
Kim DY, Kim GW, Chung SH.
Korean J Physiol Pharmacol. 2013 Oct;17(5):447-53. doi: 10.4196/kjpp.2013.17.5.447.
PMID:
24227947
Free PMC Article

21.
Tang Y, Xie H, Chen J, Geng L, Chen H, Li X, Hou Y, Lu L, Shi S, Zeng X, Sun L.
Stem Cells Dev. 2013 Feb 15;22(4):668-78. doi: 10.1089/scd.2012.0226.
22.
Kim JL, Park SH, Jeong D, Nam JS, Kang YH.
Exp Biol Med (Maywood). 2012 Apr;237(4):417-28. doi: 10.1258/ebm.2011.011376.
PMID:
22496431 Similar articles
23.
Oh JE, Kim HJ, Kim WS, Lee ZH, Ryoo HM, Hwang SJ, Lee Y, Kim HH.
J Bone Miner Res. 2012 Mar;27(3):552-62. doi: 10.1002/jbmr.1471.
PMID:
22095611Free Article 
24.
Bragdon B, D'Angelo A, Gurski L, Bonor J, Schultz KL, Beamer WG, Rosen CJ, Nohe A.
Bone. 2012 Jan;50(1):189-99. doi: 10.1016/j.bone.2011.10.016.
25.
Yamaguchi M, Arbiser JL, Weitzmann MN.
Int J Mol Med. 2011 Dec;28(6):1049-53. doi: 10.3892/ijmm.2011.786.
PMID:
21887456
26.
Lo YC, Chang YH, Wei BL, Huang YL, Chiou WF.
J Agric Food Chem. 2010 Jun 9;58(11):6643-9. doi: 10.1021/jf904158k.
PMID:
20443623
27.
Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH.
Nutr Res. 2010 Mar;30(3):191-9. doi: 10.1016/j.nutres.2010.03.004.
Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase, which catalyzes the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a rate-limiting step in cholesterol synthesis. Statins are able to reduce cardiovascular risk in hypercholesterolemic patients. In recent years, the possible effect of statins on bone tissue has received particular attention. The present study was undertaken to understand the events of osteoblast differentiation induced by statins. Our hypothesis is that simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/bone morphogenic protein (BMP)-2 signaling pathway. The viability and differentiation of osteoblasts were examined by mitochondrial activity assay, alkaline phosphatase (ALP) activity, and gene expression. The associated signaling pathways were analyzed by cytoplasmic and membrane proteins manifestation. After administration of 10(-6) M simvastatin, the ALP activity was significantly enhanced, and the expression of BMP-2, ALP, sialoprotein, and type I collagen genes were up-regulated. After simvastatin treatment, both the RasGRF1 and phospho-RasGRF1 in the cytoplasm decreased significantly, whereas those on the plasma membrane increased. A marked increase in membranous GAP-associated protein (P190) and the activated form of both phospho-extracellular signal-regulated kinase1/2 and phospho-Smad1 were also noted. In conclusion, this study shows that statins pose a positive effect on the metabolism of osteoblasts. Simvastatin can promote osteoblast viability and differentiation via membrane-bound Ras/Smad/Erk/BMP-2 pathway. Statins stimulate osteoblast differentiation in vitro and may be a promising drug for the treatment of osteoporosis in the future.
28.
Hsieh TP, Sheu SY, Sun JS, Chen MH, Liu MH.
Phytomedicine. 2010 May;17(6):414-23. doi: 10.1016/j.phymed.2009.08.007.
PMID:
19747809
29.
Sotillo Rodriguez JE, Mansky KC, Jensen ED, Carlson AE, Schwarz T, Pham L, MacKenzie B, Prasad H, Rohrer MD, Petryk A, Gopalakrishnan R.
J Bone Miner Res. 2009 Nov;24(11):1917-26. doi: 10.1359/jbmr.090507.
30.
Leong WF, Zhou T, Lim GL, Li B.
PLoS One. 2009;4(1):e4135. doi: 10.1371/journal.pone.0004135.
31.
Luppen CA, Chandler RL, Noh T, Mortlock DP, Frenkel B.
Growth Factors. 2008 Aug;26(4):226-37. doi: 10.1080/08977190802277880.
32.
Lee SU, Park SJ, Kwak HB, Oh J, Min YK, Kim SH.
Pharmacol Res. 2008 Nov-Dec;58(5-6):290-6. doi: 10.1016/j.phrs.2008.08.008.
PMID:
18822379
33.
Li B.
Endocr Metab Immune Disord Drug Targets. 2008 Sep;8(3):208-19. Review.
PMID:
18782017
34.
35.
Huang MS, Morony S, Lu J, Zhang Z, Bezouglaia O, Tseng W, Tetradis S, Demer LL, Tintut Y.
J Biol Chem. 2007 Jul 20;282(29):21237-43.
36.
Hanai J.
Clin Calcium. 2007 May;17(5):704-10. Review. Japanese.
PMID:
17470999
37.
Li Y, Li A, Strait K, Zhang H, Nanes MS, Weitzmann MN.
J Bone Miner Res. 2007 May;22(5):646-55. Erratum in: J Bone Miner Res. 2007 Jun;22(6):949.
38.
39.
García-Giralt N, Enjuanes A, Bustamante M, Mellibovsky L, Nogués X, Carreras R, Díez-Pérez A, Grinberg D, Balcells S.
Bone. 2005 May;36(5):902-8.
PMID:
15814304
40.
Chen D, Zhao M, Mundy GR.
Growth Factors. 2004 Dec;22(4):233-41. Review.
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the transforming growth factor beta (TGFbeta) superfamily. The roles of BMPs in embryonic development and cellular functions in postnatal and adult animals have been extensively studied in recent years. Signal transduction studies have revealed that Smad1, 5 and 8 are the immediate downstream molecules of BMP receptors and play a central role in BMP signal transduction

torsdag 16 oktober 2014

Osteoblasti , osteoidieritys

OSTEOBLASTI

Osteoblastit ja muut sidekudossolut ovat peräisin mesenkymaalisista kantasoluista (MSC). 
 Mesenkyymiperäinen solu on  tiettyjen luun morfogeneettisten proteiinien (BMP) vaikutuksesta  alkanut kehittyä kohti osteoprogeniittorisolua . Myös Wnt- signaalitie on pro-osteogeeninen.

 Osteoblastit ovat  luuta rakentavia soluja ja ne tuottavat ja erittävät proteiineja ja muodostavat  luun matrixia,  Osteoblasteja  soluja tavataan yksitumaisina luun pinnasta ja ne tekevät kollageeni tyyppiä I:( ECM pääkomponenttia)   ja extrasellulaarimatriksin (ECM) non-kollageenipeptidejä (NCP), osteonektiiniä, osteopontiini (OPN), luun sialoproteiinia (BSP)  ja muita  vähäisempiä luun matrixproteiineja.  ja täten vastaavat luunmuodostuksesta. Se erittää proteoglygaaneja (PG), glykoproteiineja (gp), Gla-proteiineja (osteokalsiinia OCN, MGP), metabolisia entsyymejä kuten ALP, osteoidia, joka on non-mineralisoitua ECM-osaa.
Osteoblastit ovat 4-6 % luun soluista ja niiden elinikä ihmisen luussas on kolme kuukautta.  Keskinäisessä vuorovaikutuksessa osteosyyttien   ja osteoklastien kesken  osteoblastit osaltaan   säätelevät  luun massaa ja aivan äskettäin on havaittu osteoblasteilla olevan myös endokriinisia funktioita. (2014)
Luunmuodostussyklin päätteeksi osteoblastit käyvät läpi transformation joko osteosyyteiksi, luusoluiksi tai  rajapintasoluiksi, lining cells. 
Osteoblastit , kuutionmuotoiset solut sijaitsevat yksinkertaisena kerroksena luun periostin pinnalla, eräänlaisena ”luukalvona” kuin ”luumembraanina”, jonka tehtävä on hoitaa jonivirtausta sisään ja ulos luusta ja säätää kalsiumin ja fosfaatin pitoisuuksia siten, että hydroksiapatiitin  (HA) muodostuminen edistyy. Mutta näitä erottaa varsinaisesta luupinnasta eritekerros, OSTEOIDI-kerros; tämä kerros EI ole solua, vaan eritettä ja se sisältää myös seerumiperäistä protrombiinia.
 Kun osteoidimassa vähenee, osteoblasti valitsee eri teitä. Joko apoptoosin tai muuttuu osteosyytiksi, jolloin niiden osteoidin erityskyky edelleen laskee. ( Kun osteoidi on vähentynyt, silloin vasta OSTEOKLASTI pääsee vaikuttamaan luuhun.
 Osteoidi estää osteoklastia pääsemästä luun kimppuun
  • Lining cells, rajapintasolut joita osteoblasteista voi tulla, erittävät kollagenaasia, joka poistaa kollageenimatrixia ja sallii osteoklastien hyökätä luun kimppuun. .

 Osteoblasti on polarisoitu solu ja muodostaa myös ”tight junctions”(TJ), tiiviitä liitoksia  toisiin osteoblasteihin.
Osteoblastit kommunikoivat luuytimen strooman kanssa.

LÄHDE: 

1. CARDEMIL C. Osteoblast. In:  Effects of antiresorptive agents  on inflammation and bone regeneration in different osseous sites.  2014

2.  SOMOGYI-GANSS Ester Novel non-collagenous modulators of biomineralization in bone and dentin ( 2004, KI, Stockholm) ISBN 91-7140-101-6